CAH · News · 20260807N

Regulatory Risk

CARDINAL HEALTH INC · 2026-08-07 · Importance 37 · Surprise 42

Cardinal Health is facing questions about quality controls after nationwide recalls of certain levothyroxine tablet lots by a Cardinal-affiliated distributor. The recalls could generate recall-related costs and require additional financial disclosures, although no dollar amount or timeframe was reported. The situation may also increase the risk of regulatory scrutiny of Cardinal’s pharmaceutical distribution and governance processes.

Key facts

• Simply Wall Street reported the appointment of a new Chief Accounting Officer at Cardinal Health. source